Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study

被引:3
作者
Elsamany, Shereef Ahmed [1 ,2 ]
Alghanmi, Hossam [3 ]
Albaradei, Abdelrahman [3 ]
Abdelhamid, Rasha [4 ]
Madi, Eman [4 ]
Ramzan, Amira [4 ]
机构
[1] King Abdullah Med City, Oncol Ctr, Muzdalifah Rd, Al Mashair 24246, Makkah, Saudi Arabia
[2] Mansoura Univ, Oncol Ctr, Mansoura, Egypt
[3] King Abdullah Med City, Mecca, Saudi Arabia
[4] King Abdullah Med City, Oncol Ctr, Oncol Nurse, Mecca, Saudi Arabia
关键词
Compliance; Adjuvant; Hormonal therapy; Breast cancer; ADJUVANT ENDOCRINE THERAPY; ADHERENCE; TAMOXIFEN; WOMEN; COHORT; DISCONTINUATION; NONADHERENCE;
D O I
10.1016/j.breast.2022.01.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Adherence to long-term adjuvant hormonal therapy in hormonal receptors (HR)-positive breast cancer is really challenging and can affect the survival outcome. The present study aims to assess rate of compliance with hormonal therapy and possible predictive factors in a single institute in Saudi Arabia. Patients &methods: We recruited patients with HR-positive breast cancer who presented to oncology outpatient clinics. Patients were assessed for compliance using a study questionnaire. Compliance was defined as taking >= 80% of prescribed doses of oral hormonal therapy. Different epidemiological, clinical, pathological and treatment data were checked in patients' medical records and correlated with compliance/interruption of hormonal therapy. Results: Among the 203 recruited patients, 95.1% were compliant with hormonal therapy, while it was interrupted in 16.7% of patients, and 58.1% reported missing intake of hormonal pills. Age >50 years, having permanent job and higher education level were significantly associated with non-compliance in univariate analysis. On multivariate analysis, job status was the only independent predictor of non-compliance. The following parameters were significantly related to hormonal therapy interruption: marital status (single: 28.8% vs married patients: 12.6%, p = 0.01) and residence location (Makkah: 11.7% vs. outside Makkah: 25.3%, p = 0.019), lymphovascular invasion (LVI) (No: 20.9%, Yes: 7.8%, p = 0.025) and NO tumours (compared to node-positive patients, p = 0.008). On multivariate analysis, marital status, residence location and N-stage, maintained significance relation with hormonal therapy interruption. Conclusion: Compliance with hormonal therapy was high in the study cohort. Marital status, residence location, job status and N-stage may be related to interruption/compliance with hormonal therapy.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 50 条
  • [21] Beliefs and attitudes toward endocrine therapy in patients with hormone receptor-positive breast cancer
    Kim, Yonglan
    Min, Yul Ha
    Lee, Sae Byul
    HEALTH CARE FOR WOMEN INTERNATIONAL, 2021, 42 (7-9) : 1086 - 1097
  • [22] Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer
    Bracken-Clarke, Dara B.
    Lucas, Mairi W.
    Higgins, Michaela J.
    BREAST CARE, 2017, 12 (03) : 138 - 144
  • [23] A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy
    Cecchini, Matthew J.
    Yu, Edward
    Yaremko, Brian P.
    Boldt, R. Gabriel
    Potvin, Kylea
    Sexton, Tracy
    D'Souza, David
    Brackstone, Muriel
    Lock, Michael
    CUREUS, 2016, 8 (04):
  • [24] Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?
    Alfonso Sánchez-Muñz
    Nuria Ribelles
    Emilio Alba
    Clinical and Translational Oncology, 2010, 12 : 614 - 620
  • [25] Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?
    Sanchez-Munoz, Alfonso
    Ribelles, Nuria
    Alba, Emilio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (09) : 614 - 620
  • [26] Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept
    Iwata, Hiroji
    BREAST CANCER, 2011, 18 (02) : 92 - 97
  • [27] Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)
    Abraham, Jame
    Caldera, Humberto
    Coleman, Robert
    Elias, Anthony
    Goetz, Matthew P.
    Kittaneh, Muaiad
    Lower, Elyse
    Mahtani, Reshma
    Mamounas, E. Terry
    Pegram, Mark
    Rugo, Hope
    Schwartzberg, Lee
    Traina, Tiffany
    Vogel, Chuck
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (01) : 1 - 7
  • [28] Primary Hormonal Therapy for Elderly Breast Cancer Patents: Single Institution Experience
    Panal, Mariana
    Sanchez-Mendez, Jose I.
    Revel, Rocio
    Abehsera, Daniel
    de Santiago, Javier
    Zapardiel, Ignacio
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2015, 80 (01) : 10 - 14
  • [29] Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors
    Wheeler, Stephanie Brooke
    Kohler, Racquel Elizabeth
    Reeder-Hayes, Katherine Elizabeth
    Goyal, Ravi K.
    Lich, Kristen Hassmiller
    Moore, Alexis
    Smith, Timothy W.
    Melvin, Cathy L.
    Muss, Hyman Bernard
    JOURNAL OF CANCER SURVIVORSHIP, 2014, 8 (04) : 603 - 610
  • [30] Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
    Blok, E. J.
    Derks, M. G. M.
    van der Hoeven, J. J. M.
    van de Velde, C. J. H.
    Kroep, J. R.
    CANCER TREATMENT REVIEWS, 2015, 41 (03) : 271 - 276